{"blog": [], "keywords": [{"value": "Drugs (Pharmaceuticals)", "name": "subject", "rank": "1", "is_major": "Y"}, {"value": "Johnson & Johnson", "name": "organizations", "rank": "2", "is_major": "Y"}, {"value": "Food and Drug Administration", "name": "organizations", "rank": "3", "is_major": "Y"}, {"value": "Blood Clots", "name": "subject", "rank": "4", "is_major": "Y"}, {"value": "Clinical Trials", "name": "subject", "rank": "5", "is_major": "N"}, {"value": "Recalls and Bans of Products", "name": "subject", "rank": "6", "is_major": "N"}, {"value": "Bayer AG", "name": "organizations", "rank": "7", "is_major": "N"}, {"value": "European Medicines Agency", "name": "organizations", "rank": "8", "is_major": "N"}, {"value": "Alere Inc", "name": "organizations", "rank": "9", "is_major": "N"}], "web_url": "http://www.nytimes.com/2016/02/23/business/fda-asks-if-faulty-blood-monitor-tainted-xarelto-approval.html", "document_type": "article", "byline": {"person": [{"lastname": "THOMAS", "firstname": "Katie", "role": "reported", "organization": "", "rank": 1}], "original": "By KATIE THOMAS", "contributor": "Sabrina Tavernise contributed reporting."}, "type_of_material": "News", "multimedia": [{"url": "images/2016/02/23/business/23DRUG/23DRUG-thumbWide.jpg", "legacy": {"wide": "images/2016/02/23/business/23DRUG/23DRUG-thumbWide.jpg", "wideheight": "126", "widewidth": "190"}, "subtype": "wide", "type": "image", "width": 190, "height": 126}, {"url": "images/2016/02/23/business/23DRUG/23DRUG-articleLarge.jpg", "legacy": {"xlarge": "images/2016/02/23/business/23DRUG/23DRUG-articleLarge.jpg", "xlargeheight": "405", "xlargewidth": "600"}, "subtype": "xlarge", "type": "image", "width": 600, "height": 405}, {"url": "images/2016/02/23/business/23DRUG/23DRUG-thumbStandard.jpg", "legacy": {"thumbnail": "images/2016/02/23/business/23DRUG/23DRUG-thumbStandard.jpg", "thumbnailheight": "75", "thumbnailwidth": "75"}, "subtype": "thumbnail", "type": "image", "width": 75, "height": 75}], "section_name": "Business Day", "word_count": "1420", "source": "The New York Times", "subsection_name": null, "lead_paragraph": "A legal brief says Johnson & Johnson has been asked whether Alere\u2019s recalled INRatio blood-testing monitor compromised the anticlotting drug\u2019s trial.", "pub_date": "2016-02-23T00:00:00Z", "news_desk": "Business", "headline": {"print_headline": "F.D.A. Seeks New Details in Approval of Xarelto   ", "main": "F.D.A. Asks If Faulty Blood Monitor Tainted Xarelto Approval"}, "print_page": "1", "snippet": "A legal brief says Johnson & Johnson has been asked whether Alere\u2019s recalled INRatio blood-testing monitor compromised the anticlotting drug\u2019s trial.", "_id": "56cb994338f0d80fb3eb22f1", "slideshow_credits": null, "abstract": "Food and Drug Administration is probing whether faulty blood-testing machine may have compromised results of clinical trial leading to approval of Johnson & Johnson's anticlotting drug Xarelto; will seek to understand whether warning signs were apparent to drug maker. "}